Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optic Neuritis.

Laura J. Balcer1

  • 1Division of Neuro-ophthalmology, Department of Neurology and Ophthalmology, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3 East Gates, Philadelphia, PA 19104, USA. lbalcer@mail.med.upenn.edu

Current Treatment Options in Neurology
|June 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Giant Cell Arteritis.

Current treatment options in neurology·2003
Same author

Idiopathic Intracranial Hypertension.

Current treatment options in neurology·2002
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Patients with optic neuritis showing multiple sclerosis risk factors on MRI should receive prompt treatment. Early intervention with steroids and potentially interferon beta-1a can reduce the risk of developing multiple sclerosis.

Area of Science:

  • Neurology
  • Radiology
  • Immunology

Background:

  • Acute monosymptomatic optic neuritis (AMON) is a neurological condition requiring risk assessment for multiple sclerosis (MS).
  • Gadolinium-enhanced MRI is crucial for evaluating brain and orbit lesions in AMON patients.
  • Identifying high-risk individuals aids in timely therapeutic decisions.

Purpose of the Study:

  • To outline diagnostic criteria for high-risk AMON patients.
  • To recommend treatment strategies for high-risk AMON.
  • To clarify treatment approaches for low-risk AMON and established MS.

Main Methods:

  • Gadolinium-enhanced MRI of the brain and orbits to identify white matter lesions (≥3 mm, periventricular/ovoid).
  • Intravenous methylprednisolone (1g/day for 3 days) followed by oral prednisone (1mg/kg/day for 11 days, with taper).

Related Experiment Videos

  • Consideration of interferon beta-1a (30µg IM weekly) for high-risk patients post-steroids.

    • Main Results:

    • Two or more white matter lesions indicate high risk for clinically definite multiple sclerosis (CDMS).
    • High-risk patients benefit from immediate IV methylprednisolone and oral prednisone, with interferon beta-1a reducing CDMS probability.
    • Treatment in low-risk patients or those with established CDMS may hasten visual recovery but not affect long-term outcomes.

    Conclusions:

    • MRI lesion load is key in stratifying AMON patients for MS risk.
    • Prompt treatment with steroids and potentially immunomodulators is recommended for high-risk individuals.
    • Avoid oral prednisone alone in typical AMON due to increased recurrence risk.